Skip to main content
Top
Published in: BMC Health Services Research 1/2019

Open Access 01-12-2019 | Research article

Long-term corticosteroid use and dietary advice: a qualitative analysis of the difficulties encountered by patient

Authors: Muriel Nogué, Jacques Rambaud, Sylvie Fabre, Nathalie Filippi, Christian Jorgensen, Yves-Marie Pers

Published in: BMC Health Services Research | Issue 1/2019

Login to get access

Abstract

Background

Nearly 1% of the population is currently treated with long-term corticosteroid therapy. When corticosteroids are introduced, information concerning potential adverse effects and recommendations for lifestyle changes aimed at preventing such effects is provided to patients. However, studies have shown patients often do not fully comprehend the information provided and have difficulty implementing the recommended dietary and physical activity advice. In this study, we aim to highlight the difficulties encountered by patients in comprehending and implementing recommendations in the context of long-term corticosteroid use. Such information can be used to better optimize care, particularly concerning adherence to the treatment, the diet, and thus improve the quality of life of patients.

Methods

We recruited adult patients under long-term corticosteroid (≥ 3 months, ≥ 5 mg/day) treatment from both general medicine and rheumatology practices. We performed a qualitative analysis based on semi-structured interviews of these patients. Transcripts of these interviews were then compiled and analysed using a thematic approach.

Results

Sixteen patients were included. Analysis of the interviews revealed that patients’ hope for effective corticosteroid treatment was counterbalanced by concerns over potential adverse effects. In some patients, the need to respect a strict and imposed diet induced psychological distress, potentially leading to eating disorders or fear of social exclusion. Furthermore, patient ambivalence toward the therapeutic education was highlighted, as well as the notion of filtering information, conscious or unconscious, as revealed by their lack of recall. The relationship with the physician also affected the treatment experience.

Conclusion

Our analysis of the personal experience of patients regarding recommended lifestyle changes associated with long-term corticosteroid treatment highlights patient difficulties and suggests different ways of improving therapeutic education.
Appendix
Available only for authorised users
Literature
1.
go back to reference Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine. 2014;81(6):493–501.CrossRefPubMed Briot K, Cortet B, Roux C, Fardet L, Abitbol V, Bacchetta J, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine. 2014;81(6):493–501.CrossRefPubMed
2.
go back to reference Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996;313(7053):344–6.CrossRefPubMedPubMedCentral Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996;313(7053):344–6.CrossRefPubMedPubMedCentral
3.
go back to reference Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 2013;65(2):294–8.CrossRef Overman RA, Yeh J-Y, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 2013;65(2):294–8.CrossRef
4.
go back to reference Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM Mon J Assoc Physicians. 2000;93(2):105–11.CrossRef Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM Mon J Assoc Physicians. 2000;93(2):105–11.CrossRef
5.
go back to reference Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011;50(11):1982–90.CrossRefPubMed Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011;50(11):1982–90.CrossRefPubMed
6.
go back to reference Perdoncini-Roux A, Blanchon T, Hanslik T, Lasserre A, Turbelin C, Dorleans Y, et al. Description of French general practitioners’ practices regarding long term systemic corticosteroid therapy-associated measures. Rev Prat. 2009;59(8 Suppl):19–24.PubMed Perdoncini-Roux A, Blanchon T, Hanslik T, Lasserre A, Turbelin C, Dorleans Y, et al. Description of French general practitioners’ practices regarding long term systemic corticosteroid therapy-associated measures. Rev Prat. 2009;59(8 Suppl):19–24.PubMed
8.
go back to reference Fardet L, Kettaneh A, Gérol J, Tolédano C, Tiev K-P, Cabane J. Effet à court terme des apports sodés sur la pression artérielle des patients recevant une corticothérapie systémique : étude prospective, randomisée, croisée. Rev Méd Interne. 2009;30(9):741–6.CrossRefPubMed Fardet L, Kettaneh A, Gérol J, Tolédano C, Tiev K-P, Cabane J. Effet à court terme des apports sodés sur la pression artérielle des patients recevant une corticothérapie systémique : étude prospective, randomisée, croisée. Rev Méd Interne. 2009;30(9):741–6.CrossRefPubMed
9.
go back to reference Sailler L, Pugnet G, Arlet P. Corticothérapie systémique: les mesures d’accompagnement. Rev Méd Interne. 2013;34(5):279–83.CrossRefPubMed Sailler L, Pugnet G, Arlet P. Corticothérapie systémique: les mesures d’accompagnement. Rev Méd Interne. 2013;34(5):279–83.CrossRefPubMed
10.
go back to reference Baldomir E. Les effets indésirables de la corticothérapie au long cours. Mesures adjuvantes et conseils lors de la délivrance à l’officine [Internet]. [Limoges]: Faculté de pharmacie; 2011. Available from: file:///C:/Users/01000754/Downloads/P20113365.pdf. Baldomir E. Les effets indésirables de la corticothérapie au long cours. Mesures adjuvantes et conseils lors de la délivrance à l’officine [Internet]. [Limoges]: Faculté de pharmacie; 2011. Available from: file:///C:/Users/01000754/Downloads/P20113365.pdf.
11.
go back to reference Fardet L, Hanslik T, Blanchon T, Perdoncini-Roux A, Kettaneh A, Tiev KP, et al. Mesures adjuvantes à une corticothérapie systémique prolongée : description des pratiques des médecins internistes français. Rev Méd Interne. 2008;29(12):975–80.CrossRefPubMed Fardet L, Hanslik T, Blanchon T, Perdoncini-Roux A, Kettaneh A, Tiev KP, et al. Mesures adjuvantes à une corticothérapie systémique prolongée : description des pratiques des médecins internistes français. Rev Méd Interne. 2008;29(12):975–80.CrossRefPubMed
12.
go back to reference Lamchahab FE, Reffas W, Bouattar T, Abdellaoui EK, Ouzeddoun N, Bayahia R, et al. Mesures adjuvantes à une corticothérapie systémique prolongée : que faut-il prescrire ? Ann Pharm Fr. 2012;70(5):292–7.CrossRefPubMed Lamchahab FE, Reffas W, Bouattar T, Abdellaoui EK, Ouzeddoun N, Bayahia R, et al. Mesures adjuvantes à une corticothérapie systémique prolongée : que faut-il prescrire ? Ann Pharm Fr. 2012;70(5):292–7.CrossRefPubMed
13.
go back to reference Zerah L, Arena C, Morin A-S, Blanchon T, Cabane J, Fardet L. Le ressenti des patients vis-à-vis d’une corticothérapie orale prolongée influence l’adhérence déclarée à ce traitement. Rev Méd Interne. 2012;33(6):300–4.CrossRefPubMed Zerah L, Arena C, Morin A-S, Blanchon T, Cabane J, Fardet L. Le ressenti des patients vis-à-vis d’une corticothérapie orale prolongée influence l’adhérence déclarée à ce traitement. Rev Méd Interne. 2012;33(6):300–4.CrossRefPubMed
14.
go back to reference Arena C, Morin A-S, Blanchon T, Hanslik T, Cabane J, Dupuy A, et al. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy: adverse events and adherence to glucocorticoids. Br J Dermatol. 2010;163(4):832–7.CrossRefPubMed Arena C, Morin A-S, Blanchon T, Hanslik T, Cabane J, Dupuy A, et al. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy: adverse events and adherence to glucocorticoids. Br J Dermatol. 2010;163(4):832–7.CrossRefPubMed
15.
go back to reference Nassar K, Janani S, Roux C, Rachidi W, Etaouil N, Mkinsi O. La corticothérapie systémique au long cours : représentations des patients, perceptions des prescripteurs et observance thérapeutique. Rev Rhum. 2014;81(1):49–53.CrossRef Nassar K, Janani S, Roux C, Rachidi W, Etaouil N, Mkinsi O. La corticothérapie systémique au long cours : représentations des patients, perceptions des prescripteurs et observance thérapeutique. Rev Rhum. 2014;81(1):49–53.CrossRef
16.
go back to reference Gil H, Méaux-Ruault N, Magy-Bertrand N, Hafsaoui C, Dupond J-L. Corticothérapie prolongée: impact sur la qualité de vie des patients.« la cortisone⋯est-ce vraiment l’enfer? ». Rev. Méd Interne. 2006;27:S323–4.CrossRef Gil H, Méaux-Ruault N, Magy-Bertrand N, Hafsaoui C, Dupond J-L. Corticothérapie prolongée: impact sur la qualité de vie des patients.« la cortisone⋯est-ce vraiment l’enfer? ». Rev. Méd Interne. 2006;27:S323–4.CrossRef
17.
go back to reference Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T, Tolédano C, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?S opinion. Br J Dermatol. 2007;157(1):142–8.CrossRefPubMed Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T, Tolédano C, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?S opinion. Br J Dermatol. 2007;157(1):142–8.CrossRefPubMed
18.
go back to reference Fardet L, Blanchon T, Perdoncini-Roux A, Kettaneh A, Tiev K, Turbelin C, et al. Perception par les médecins internistes de la fréquence et de la gêne induite par les effets indésirables d’une corticothérapie systémique prolongée. Rev Méd Interne. 2009;30(2):113–8.CrossRefPubMed Fardet L, Blanchon T, Perdoncini-Roux A, Kettaneh A, Tiev K, Turbelin C, et al. Perception par les médecins internistes de la fréquence et de la gêne induite par les effets indésirables d’une corticothérapie systémique prolongée. Rev Méd Interne. 2009;30(2):113–8.CrossRefPubMed
19.
go back to reference Perdoncini-Roux A, Blanchon T, Hanslik T, Lasserre A, Turbelin C, Dorleans Y, et al. Perception par les médecins généralistes de la gêne induite par les effets indésirables d’une corticothérapie systémique prolongée. Rev DÉpidémiologie Santé Publique. 2009;57(2):93–7.CrossRef Perdoncini-Roux A, Blanchon T, Hanslik T, Lasserre A, Turbelin C, Dorleans Y, et al. Perception par les médecins généralistes de la gêne induite par les effets indésirables d’une corticothérapie systémique prolongée. Rev DÉpidémiologie Santé Publique. 2009;57(2):93–7.CrossRef
20.
go back to reference Riviere S, Konate A, Ceballos P, Crozat S, Le quellec A. Tolérance de la corticothérapie: Prise en charge diététique et suivi du régime. Résultats préliminaires. Rev Méd Interne. 2002;23:73.CrossRef Riviere S, Konate A, Ceballos P, Crozat S, Le quellec A. Tolérance de la corticothérapie: Prise en charge diététique et suivi du régime. Résultats préliminaires. Rev Méd Interne. 2002;23:73.CrossRef
21.
go back to reference Fardet L, Flahault A, Kettaneh A, Tiev K-P, Tolédano C, Lebbe C, et al. Corticothérapie systémique et alimentation: suivi des recommandations diététiques et relation entre apports alimentaires et apparition d’une lipodystrophie. Rev Méd Interne. 2007;28(5):284–8.CrossRefPubMed Fardet L, Flahault A, Kettaneh A, Tiev K-P, Tolédano C, Lebbe C, et al. Corticothérapie systémique et alimentation: suivi des recommandations diététiques et relation entre apports alimentaires et apparition d’une lipodystrophie. Rev Méd Interne. 2007;28(5):284–8.CrossRefPubMed
22.
go back to reference Jacquelin N, Bouillet L, Massot C. Vécu de la corticothérapie en cure prolongée:D’après une enquête réalisée auprès de 100 patients. Rev Méd Générale. 2002;23(S1):73–4. Jacquelin N, Bouillet L, Massot C. Vécu de la corticothérapie en cure prolongée:D’après une enquête réalisée auprès de 100 patients. Rev Méd Générale. 2002;23(S1):73–4.
23.
go back to reference Simon A, Ané A-M, Afroun A. Corticoïdes et éducation thérapeutique : expérience d’un service de médecine interne. Rev Méd Interne. 2013;34(5):287–92.CrossRefPubMed Simon A, Ané A-M, Afroun A. Corticoïdes et éducation thérapeutique : expérience d’un service de médecine interne. Rev Méd Interne. 2013;34(5):287–92.CrossRefPubMed
24.
go back to reference Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.CrossRefPubMed Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.CrossRefPubMed
25.
go back to reference Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JAM, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008;64(1):47–54.CrossRefPubMed Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JAM, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res. 2008;64(1):47–54.CrossRefPubMed
26.
go back to reference Paillé P, Mucchielli A. L’analyse qualitative en sciences humaines et sociales. Paris: A. Colin; 2013. Paillé P, Mucchielli A. L’analyse qualitative en sciences humaines et sociales. Paris: A. Colin; 2013.
27.
go back to reference Turato ER. Qualitative and quantitative methods in health: definitions, differences and research subjects. Rev Saude Publica. 2005;39(3):507–14.CrossRefPubMed Turato ER. Qualitative and quantitative methods in health: definitions, differences and research subjects. Rev Saude Publica. 2005;39(3):507–14.CrossRefPubMed
28.
go back to reference Aubin-Auger I, Mercier A, Baumann L, Lehr-Drylewicz A-M, Imbert P, Letrilliart L. Introduction à la recherche qualitative. Exercer. 2008;84(19):142–5. Aubin-Auger I, Mercier A, Baumann L, Lehr-Drylewicz A-M, Imbert P, Letrilliart L. Introduction à la recherche qualitative. Exercer. 2008;84(19):142–5.
29.
go back to reference Hummers-Pradier E, Scheidt-Nave C, Martin H, Heinemann S, Himmel W. Simply no time? Barriers to GPs’ participation in primary health care research. Fam Pract. 2008;225(2):105–12.CrossRef Hummers-Pradier E, Scheidt-Nave C, Martin H, Heinemann S, Himmel W. Simply no time? Barriers to GPs’ participation in primary health care research. Fam Pract. 2008;225(2):105–12.CrossRef
30.
go back to reference Vietch C, Hollins J, Worley P, Mitchell G. General practice research. Problems and solutions in participant recruitment and retention. Aust Fam Physician. 2001;30(4):399–406. Vietch C, Hollins J, Worley P, Mitchell G. General practice research. Problems and solutions in participant recruitment and retention. Aust Fam Physician. 2001;30(4):399–406.
31.
go back to reference Coppa K, Boyle F. The role of self-help groups in chronic illness management: a qualitative study. Aust J Prim Health. 2003;9(3):68–74.CrossRef Coppa K, Boyle F. The role of self-help groups in chronic illness management: a qualitative study. Aust J Prim Health. 2003;9(3):68–74.CrossRef
32.
go back to reference Zermati J-P. Maigrir sans régime. Paris: O. Jacob; 2013. Zermati J-P. Maigrir sans régime. Paris: O. Jacob; 2013.
34.
go back to reference Poisson J, Six M, Morin C, Fardet L. Corticoïdes et corticothérapies: quelle est l’information recherchée par les patients ? Analyse des visites du site Internet cortisone-info.fr. Rev Méd Interne. 2013;34(5):255–7.CrossRefPubMed Poisson J, Six M, Morin C, Fardet L. Corticoïdes et corticothérapies: quelle est l’information recherchée par les patients ? Analyse des visites du site Internet cortisone-info.fr. Rev Méd Interne. 2013;34(5):255–7.CrossRefPubMed
35.
go back to reference Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–13.CrossRefPubMed Duru N, van der Goes MC, Jacobs JWG, Andrews T, Boers M, Buttgereit F, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–13.CrossRefPubMed
36.
go back to reference Repesse A. Representation sociale de la corticotherapie de courte duree dans la population générale. Faculté de médecine de Grenoble: Université Joseph Fourier; 2010. Repesse A. Representation sociale de la corticotherapie de courte duree dans la population générale. Faculté de médecine de Grenoble: Université Joseph Fourier; 2010.
38.
go back to reference LOI n° 2012–300 du 5 mars 2012 relative aux recherches impliquant la personne humaine.JORF n°0056. 2012: p 4138. LOI n° 2012–300 du 5 mars 2012 relative aux recherches impliquant la personne humaine.JORF n°0056. 2012: p 4138.
Metadata
Title
Long-term corticosteroid use and dietary advice: a qualitative analysis of the difficulties encountered by patient
Authors
Muriel Nogué
Jacques Rambaud
Sylvie Fabre
Nathalie Filippi
Christian Jorgensen
Yves-Marie Pers
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2019
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-019-4052-y

Other articles of this Issue 1/2019

BMC Health Services Research 1/2019 Go to the issue